Table 2.

The top 10 cited articles in PTLD

Authors	Year	Title	Source title	Cited by
Chen BJ	2013	PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies	Clinical Cancer Research	585
Haque T	2007	Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial	Blood	441
Durrbach A	2010	A Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT-EXT Study)	American Journal of Transplantation	386
Choquet S	2006	Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study	Blood	299
Caillard S	2005	Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression	Transplantation	298
Penn I	2000	Post-transplant malignancy - The role of immunosuppression	Drug Safety	293
Taylor AL	2005	Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation	Critical Reviews in Oncology Hematology	271
Haque T	2002	Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells	Lancet	266
Landgren O	2009	Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation	Blood	260
Socie G	2000	New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia	Journal of Clinical Oncology	250

EBV,Epstein-Bar virus; PTLD,post-transplant lymphoproliferative disease.